AVXL ANAVEX LIFE SCIENCES CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | $4.19M | $4.66M | $7.29M | $9.96M | $9.89M | $10.45M | $11.55M |
| SG&A expense | $2.03M | $2.29M | $2.13M | $3.55M | $4.50M | $2.62M | $3.15M | $2.78M |
| Operating income | $6.74M | -$6.48M | -$6.78M | -$10.84M | -$14.46M | -$12.51M | -$13.59M | -$14.34M |
| Pretax income | — | — | — | — | — | — | — | -$11.74M |
| Income tax | $0 | $0 | $18,000 | — | — | — | — | — |
| Net income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | -$11.20M | -$12.11M | -$11.62M |
| EPS (basic) | 0.08 | -0.06 | -0.06 | — | -0.16 | -0.13 | -0.14 | — |
| EPS (diluted) | 0.08 | -0.06 | -0.06 | — | -0.16 | -0.13 | -0.14 | — |
| Weighted avg. shares (diluted) | 92.90B | 92.68M | 89.03M | — | 85.38B | 85.07M | 84.81M | — |
| Banking | ||||||||
| Net interest income | $1.07M | $1.06M | $1.08M | $999,000 | $1.07M | $1.21M | $1.39M | $1.76M |
| Balance sheet | ||||||||
| Cash & equivalents | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | $115.77M | $120.78M | $132.19M |
| Total assets | $120.14M | $128.77M | $132.99M | $103.81M | $102.43M | $117.14M | $124.04M | $135.57M |
| Total liabilities | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | $17.38M | $13.13M | $15.30M |
| Shareholders' equity | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | $99.76M | $110.92M | $120.26M |
| Shares outstanding | 92.70M | 92.70M | 92.67M | 86.67M | 85.41M | 85.33M | 84.99M | 84.80M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.10M | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -$5.86M | -$12.12M | -$6.66M |
| Financing cash flow | $0 | $113,000 | $36.32M | $10.02M | -$2.14M | $852,000 | $708,000 | $89,000 |
| Stock-based compensation | -$17.08M | $314,000 | $1.11M | $3.72M | $4.32M | $1.45M | $2.06M | $2.01M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.